Business
Microbix Completes Continuous Disclosure Review With Ontario Securities Commission
Microbix Completes Continuous Disclosure Review With Ontario Securities Commission.
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"\n\n\n\n\n>\n\nTORONTO, Sept. 7 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) today\nannounced refiling revised Management Discussion and Analysis (\"MD&A\") for the\nyear ended September 30, 2005 as a result of its participation in the Ontario\nSecurities Commission Continuous Disclosure Review Program.\nThe revised MD&A includes additional discussion and analysis of the\nCompany's business generally, factors affecting financial performance,\nenhanced selected annual financial data and selected quarterly financial data,\nfourth quarter 2005 analysis, expanded discussion of future liquidity and\ncapital needs, details of related party transactions, expanded risk factors\nand description of management's evaluation of the effectiveness of its\ndisclosure controls and procedures.\n\nAbout Microbix\nMicrobix specializes in developing proprietary biological technologies\nand commercializing them through global partners. The Company has intellectual\nproperty in large market biotherapeutic drugs, vaccine technologies and animal\nreproduction technologies. Established in 1988, Microbix is headquartered in\nToronto.\n\nThis press release contains forward-looking statements, which are subject\nto risks and uncertainties that could cause actual results to differ\nmaterially from those set forth in the forward-looking statements including\nthe risks associated with failure to develop and commercialize, non-adoption,\nresistance to business model for commercialization and implementation; risk\nassociated with operation and maintenance of facilities; risks associated with\ncommercializing technology; and risks associated with margins due to\nappreciation of the Canadian dollar, among others. These forward-looking\nstatements represent the Company's judgment as of the date of this press\nrelease. The Company disclaims any intent or obligation to update these\nforward-looking statements.\n\n%SEDAR: 00004220E\n\n\n","length":2034,"tagName":"div"}]